Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT ID: NCT05348577
Last Updated: 2025-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1035 participants
INTERVENTIONAL
2022-03-25
2026-03-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT03761225
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT01718353
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
NCT01308567
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
NCT00744497
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
NCT06890832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Capivasertib and placebo film-coated tablets will be identical in appearance and presented in the same packaging to ensure blinding of the capivasertib.
All personnel involved with the statistical analysis of the study will remain blinded until database lock and CSP deviations have been identified.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
capivasertib + docetaxel
Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.
capivasertib
320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.
Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
docetaxel
Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
placebo + docetaxel
Participants receive placebo in combination with docetaxel and steroids on a background of ADT.
docetaxel
Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
placebo
matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
capivasertib
320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.
Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
docetaxel
Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
placebo
matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion (defined as 1 lesion with positive uptake on bone scan) and/or ≥ 1 soft tissue lesion (measurable or non-measurable)
* Patient must have been previously treated with a next generation hormonal agent (NHA), ie, abiraterone, enzalutamide, apalutamide or darolutamide, for prostate cancer for at least 3 months and shown evidence of disease progression (radiological or via PSA assessment) while receiving the NHA
* Evidence of mCRPC with progression of disease despite androgen deprivation therapy (ADT)
* Serum testosterone level ≤ 50 ng/dL
* Candidate for docetaxel and steroid therapy
* Ongoing ADT with LHRH agonist, LHRH antagonist, or bilateral orchiectomy
* Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1 and anticipated minimum life expectancy of 12 weeks
* Confirmation that archival formalin-fixed paraffin-embedded (FFPE) tumour tissue sample which meets the minimum pathology and sample requirements is available to send to the central laboratory
* Able and willing to swallow and retain oral medication
* Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
Exclusion Criteria
* Major surgery (excl. placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, internal stents) within 4 weeks of start of study treatment
* Brain metastases,or spinal cord compression (unless spinal cord compression is asymptomatic and stable and not requiring steroids for at least 4 weeks prior to start of study treatment)
* Any of the following cardiac criteria:
i. Mean resting corrected QT interval (QTc) \>470 msec from 3 consecutive ECGs ii. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG iii. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age,or any concomitant medication known to prolong the QT interval iv. Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade ≥2 v. Symptomatic hypotension - systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg vi. haemodinamic instability
* Clinically significant abnormalities of glucose metabolism as defined by any of the following:
i. Patients with diabetes mellitus (DM) type 1 or DM type 2 requiring insulin treatment ii. HbA1c ≥8.0% (63.9 mmol/mol)
* Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
i. Absolute neutrophil count \< 1.5x 10\^9/L ii. Platelet count \< 100x 10\^9/L iii. Haemoglobin \< 9 g/dL (\< 5.59 mmol/L) iv. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2.5x upper limit of normal (ULN) if no demonstrable liver metastases or \> 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total bilirubin \> 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. Creatinine clearance \< 50 mL/min per the Cockcroft and Gault formula without the need for chronic dialysis;
* As judged by the investigator, any evidence of diseases (including severe or uncontrolled systemic diseases, uncontrolled hypertension, history of interstitial pneumonia / pneumonitis or interstitial lung disease, renal transplant and active bleeding diseases), which, in the investigator's opinion, makes it undesirable for the patient to participate in the study or that would jeopardise compliance with the protocol.
* Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib
* Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent. Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent.
* Previous allogeneic bone marrow transplant or solid organ transplant
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.
* Persistent toxicities (CTCAE Grade ≥2) caused by previous anticancer therapy, excluding alopecia. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss)
* Known to have active hepatitis infection.
* Known to have human immunodeficiency virus (HIV) with a detectable viral RNA load or a CD4+ T-cell count \< 350 cells/uL or a history of an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months, or receiving anti-HIV medications for less than 4 weeks.
* Known to have active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
* Treatment with any of the following:
i. Prior chemotherapy for CRPC. Chemotherapy for metastatic or localized HSPC (including docetaxel) is allowed provided that chemotherapy was completed ≥ 6months before randomisation and progression of the prostate cancer occurred ≥ 6months after the completion of therapy.
ii. Prior exposure to AKT inhibitors or PI3K inhibitors iii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iv. Any other immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents (except ADT) within 3 weeks of the first dose of study treatment v. Strong inhibitors or strong inducers of cytochrome P450 (CYP)3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), vi.Use of any live vaccine administration 30 days prior to the initiation of study treatment, during, and for at least 90 days after the last dose of the study treatment
* Drugs known to significantly prolong the QT interval and associated with Torsade de Pointes within 5 half-lives of the first dose of study treatment
* History of hypersensitivity to active or inactive excipients of capivasertib, docetaxel, or drugs with a similar chemical structure or class
* Any restriction or contraindication based on the local prescribing information that would prohibit the use of docetaxel
18 Years
130 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Yuma, Arizona, United States
Research Site
Beverly Hills, California, United States
Research Site
Cerritos, California, United States
Research Site
Fresno, California, United States
Research Site
Los Angeles, California, United States
Research Site
Sacramento, California, United States
Research Site
San Francisco, California, United States
Research Site
Santa Barbara, California, United States
Research Site
Santa Monica, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Aurora, Colorado, United States
Research Site
Lakewood, Colorado, United States
Research Site
Littleton, Colorado, United States
Research Site
Baltimore, Maryland, United States
Research Site
Baltimore, Maryland, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Hackensack, New Jersey, United States
Research Site
Albany, New York, United States
Research Site
The Bronx, New York, United States
Research Site
White Plains, New York, United States
Research Site
Toledo, Ohio, United States
Research Site
Portland, Oregon, United States
Research Site
Bala-Cynwyd, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Greenville, South Carolina, United States
Research Site
Watertown, South Dakota, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Kingwood, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Chesapeake, Virginia, United States
Research Site
Seattle, Washington, United States
Research Site
Birtinya, , Australia
Research Site
Greenslopes, , Australia
Research Site
Kogarah, , Australia
Research Site
North Adelaide, , Australia
Research Site
Orange, , Australia
Research Site
Redcliffe, , Australia
Research Site
Wahroonga, , Australia
Research Site
Brasschaat, , Belgium
Research Site
Ghent, , Belgium
Research Site
Liège, , Belgium
Research Site
Cachoeiro de Itapemirim, , Brazil
Research Site
Ijuí, , Brazil
Research Site
Itajaí, , Brazil
Research Site
Joinville, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Recife, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
Salvador, , Brazil
Research Site
Salvador, , Brazil
Research Site
Santa Maria, , Brazil
Research Site
São José Do Rio Preto - SP, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Três Lagoas, , Brazil
Research Site
Halifax, Nova Scotia, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Toronto, , Canada
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Viña del Mar, , Chile
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changsha, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Chengdu, , China
Research Site
Chongqing, , China
Research Site
Guangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Harbin, , China
Research Site
Jiaxing, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Nantong, , China
Research Site
Ningbo, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Tianjin, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Yantai, , China
Research Site
Zhengzhou, , China
Research Site
Hořovice, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Pardubice, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Bordeaux, , France
Research Site
Brest, , France
Research Site
Clermont-Ferrand, , France
Research Site
Créteil, , France
Research Site
Montpellier, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Rouen, , France
Research Site
Saint-Herblain, , France
Research Site
Saint-Mandé, , France
Research Site
Strasbourg, , France
Research Site
Strasbourg, , France
Research Site
Vandœuvre-lès-Nancy, , France
Research Site
Villejuif, , France
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Chaïdári, , Greece
Research Site
Marousi, , Greece
Research Site
Pátrai, , Greece
Research Site
Piraeus, , Greece
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Szeged, , Hungary
Research Site
Szolnok, , Hungary
Research Site
Bikaner, , India
Research Site
Meerut, , India
Research Site
Mohali, , India
Research Site
New Delhi, , India
Research Site
Be’er Ya‘aqov, , Israel
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Kfar Saba, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Ramat Gan, , Israel
Research Site
Tel Aviv, , Israel
Research Site
Chiba, , Japan
Research Site
Hirakata-shi, , Japan
Research Site
Hirosaki-shi, , Japan
Research Site
Kanazawa, , Japan
Research Site
Kashihara-shi, , Japan
Research Site
Kita-gun, , Japan
Research Site
Kobe, , Japan
Research Site
Kumamoto, , Japan
Research Site
Miyazaki, , Japan
Research Site
Nagano, , Japan
Research Site
Nagoya, , Japan
Research Site
Nakano, , Japan
Research Site
Osaka, , Japan
Research Site
Osakasayama-shi, , Japan
Research Site
Sagamihara-shi, , Japan
Research Site
Sapporo, , Japan
Research Site
Tsu, , Japan
Research Site
Wakayama, , Japan
Research Site
Yokohama, , Japan
Research Site
Aguascalientes, , Mexico
Research Site
Culiacán, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Mexico City, , Mexico
Research Site
México, , Mexico
Research Site
Oaxaca City, , Mexico
Research Site
Zapopan, , Mexico
Research Site
Hoofddorp, , Netherlands
Research Site
The Hague, , Netherlands
Research Site
Nowa Sól, , Poland
Research Site
Opole, , Poland
Research Site
Wieliszew, , Poland
Research Site
Bukgu, , South Korea
Research Site
Busan, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Córdoba, , Spain
Research Site
Lugo, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Málaga, , Spain
Research Site
Sabadell, , Spain
Research Site
Seville, , Spain
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Adana, , Turkey (Türkiye)
Research Site
Edirne, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Şahinbey, , Turkey (Türkiye)
Research Site
Yüreğir, , Turkey (Türkiye)
Research Site
Edinburgh, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Guildford, , United Kingdom
Research Site
Hackensack, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Southampton, , United Kingdom
Research Site
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504996-26-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2021-005201-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D361EC00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.